Document Detail


Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients.
MedLine Citation:
PMID:  19247267     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The effect on endothelium-dependent and independent vasodilation of 24-week treatment with a fixed-dose combination of perindopril/indapamide (2/0.625 mg, daily) and atenolol (50 mg, daily), was evaluated in 62 untreated essential hypertensive patients according a double-blind, parallel group, randomized study.
METHODS: Brachial artery flow-mediated dilation (FMD), response to sublingual glyceril trinitrate (GTN, 25 microg) and to cold pressor test (CPT) were measured at baseline and after treatments at 12 and 24 weeks, as change in diameter from ultrasound scans by a computerized system.
RESULTS: Blood pressure (BP) was (P < 0.001) reduced in both groups, but to a greater (P < 0.01) extent in the perindopril/indapamide group. After 24 weeks, FMD was significantly increased (P < 0.01) by perindopril/indapamide (from 5.0 +/- 2.1 to 6.0 +/- 1.7%) but not by atenolol (from 5.1 +/- 1.8 to 5.5 +/- 1.8%). Improvement in FMD was not statistically related to BP reduction. Response to GTN was also significantly (P < 0.05) increased by perindopril/indapamide (from 6.2 +/- 1.9 to 6.9 +/- 1.7%), but not by atenolol (from 6.1 +/- 2.8 to 6.6 +/- 2.6%). Improvement in GTN response was significantly (P < 0.05) related to BP reduction. Response to CPT was significantly increased (P < 0.001) by perindopril/indapamide after 12 and 24 weeks, whereas atenolol significantly (P < 0.05) improved it only after 24 weeks.
CONCLUSIONS: Treatment with perindopril/indapamide improves endothelium-dependent vasodilation in comparison with atenolol. This improvement was observed without significant relations with BP changes, suggesting a pressure-independent effect. Improvement in endothelium-independent and sympathetic-associated vasodilation was also observed. These results suggests that long term therapy with a fixed-dose combination of perindopril/indapamide affords vascular protection in hypertensive patients.
Authors:
Lorenzo Ghiadoni; Armando Magagna; Isabella Kardasz; Stefano Taddei; Antonio Salvetti
Related Documents :
7957537 - Antihypertensive efficacy of twice daily controlled release diltiazem using 24 hour int...
1675867 - A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure a...
1316047 - Hemodynamic collapse following labetalol administration in preeclampsia.
17326337 - A large scale study of angiotensin ii inhibition therapy in an elderly population: the ...
23722907 - Immune cells control skin lymphatic electrolyte homeostasis and blood pressure.
9566087 - Evaluation of oxygen and pressure in treatment of decompression sickness in guinea pigs.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2009-02-26
Journal Detail:
Title:  American journal of hypertension     Volume:  22     ISSN:  1941-7225     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-23     Completed Date:  2009-05-28     Revised Date:  2011-06-30    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  506-12     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Pisa, Pisa, Italy. l.ghiadoni@med.unipi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antihypertensive Agents / administration & dosage
Atenolol / therapeutic use
Brachial Artery / drug effects
Drug Combinations
Female
Humans
Hypertension / drug therapy*
Indapamide / administration & dosage*
Male
Middle Aged
Nitroglycerin / pharmacology
Perindopril / administration & dosage*
Vasodilation / drug effects
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Drug Combinations; 26807-65-8/Indapamide; 29122-68-7/Atenolol; 55-63-0/Nitroglycerin; 82834-16-0/Perindopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus a...
Next Document:  Predicting physical activity energy expenditure using accelerometry in adults from sub-Sahara Africa...